Fulgent Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Decisions with the Full Value Chain Report
This Fulgent Value Chain Analysis helps you quickly understand how Fulgent creates value across support and primary activities in a clear, practical format. This page already shows a real preview of the actual analysis, so you can review the content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Fulgent Genetics needs tight firm infrastructure because its clinical diagnostics platform depends on quality systems, regulatory oversight, and finance controls to keep reimbursement and compliance on track. In FY2025, that mattered more as the business had to coordinate multiple test lines, from oncology to rare disease, while protecting margins in a low-volume lab model. Strong finance and compliance teams also help reduce claim denials and support payer relationships.
Human Resource Management
Fulgent's human resource management depends on hiring and training molecular scientists, laboratory technologists, bioinformaticians, and commercial staff. In 2025, that matters because lab accuracy and turnaround time hinge on skilled teams, and even small staffing gaps can slow physician support. Strong training also helps protect quality systems, which is critical in a diagnostics business where errors can hit revenue and customer trust fast.
Technology Development
Fulgent Genetics' technology development is built on proprietary DNA sequencing and bioinformatics, which keep assay design, automation, and data interpretation in-house. In fiscal 2025, that model still supports a broad test menu and faster product updates, so the Fulgent Genetics value chain stays differentiated on speed and test quality. One line: control of the lab tech stack is the moat.
Procurement
Procurement at Fulgent Genetics centers on sourcing reagents, consumables, instruments, and cloud computing with tight quality control, because small input failures can disrupt test output and timelines. Efficient buying matters: every basis-point drop in supply cost helps lower cost per test and protect margins in a low-margin diagnostics business. In 2025, that discipline also supports steadier service when demand shifts, since reliable vendors and inventory buffers reduce stockout risk.
Fulgent Genetics' FY2025 support engine: quality, speed, and discipline
Fulgent Genetics' support activities in FY2025 centered on keeping a regulated, tech-heavy lab model tight: firm infrastructure, skilled staff, in-house assay development, and disciplined sourcing all protect test quality and turnaround time.
| Support activity | FY2025 focus |
|---|---|
| Infrastructure | Compliance, finance, reimbursement |
| HR | Molecular and bioinformatics talent |
| Tech development | Sequencing and data interpretation |
| Procurement | Reagents, instruments, cloud |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Fulgent's inbound logistics starts with specimens and orders from physicians, health systems, and partner channels, moving through collection kits and courier networks. Before testing begins, accessioning and sample quality checks protect chain of custody and reduce rework. Fulgent did not separately disclose 2025 specimen intake counts or inbound freight spend, so the key value driver is still fast, clean sample receipt.
Operations
Fulgent Genetics operations turn patient samples into clinically actionable reports through sequencing, bioinformatics, and expert review. This is the core value step that links lab throughput to real use in rare disease, oncology, reproductive health, and infectious disease. In 2025, the same workflow stays central to margin and scale, because faster turnaround and higher test yield drive more reported cases per sample.
Outbound Logistics
Fulgent delivers results electronically to ordering physicians, care teams, and institutional customers, so clinical teams can act faster after a test is finished. In fiscal 2025, that digital outbound flow is central to Fulgent's lab service model because secure report delivery cuts handoff delays and lowers the chance of manual error. Faster turnaround from result release to review helps speed diagnosis, treatment choices, and follow-up testing.
Marketing and Sales
In 2025, Fulgent's marketing and sales effort centered on physician education, specialty outreach, and reimbursement support, which helps turn its testing platform into repeat orders. In diagnostics, payer access and physician ordering habits matter more than broad ads, so strong commercial execution can lift recurring test volume and protect margin.
Service
Fulgent's service activity extends beyond test delivery with post-test support that includes report clarification, customer support, and variant reanalysis when needed. That helps physicians read results the right way and lowers the risk of misuse in care decisions. In 2025, this kind of support is a key value driver because it turns lab output into usable clinical guidance and builds trust in the platform.
Fulgent's 2025 edge: faster sequencing, stronger payer access, recurring orders
Fulgent's primary activities in fiscal 2025 were sample intake, sequencing, and report delivery; the value driver was speed and accuracy, not volume disclosure. 2025 sales and service work focused on physician outreach, payer access, and post-test support, which keeps orders recurring.
| Activity | 2025 data |
|---|---|
| Core ops | Sequencing, bioinformatics, review |
| Commercial focus | Physician, payer, support |
Preview Before You Purchase
Fulgent Reference Sources
You're viewing a live preview of the actual Fulgent Value Chain Analysis document. The full version you receive after purchase is the same professional, detailed file shown here – no sample or placeholder content. Buy now to unlock the complete report in its full, ready-to-use format.
Frequently Asked Questions
Technology development and operations drive most value. Fulgent Genetics turns a specimen into a clinical report through its proprietary platform, which links advanced DNA sequencing with bioinformatics. That model spans 4 application areas-rare disease, oncology, reproductive health, and infectious disease-and depends on 2 tightly connected layers: lab execution and data interpretation.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.